Tech Company Financing Transactions

Acceleron Pharma Funding Round

Acceleron Pharma, based in Cambridge, scored $31 million from Bessemer Venture Partners, Advanced Technology Ventures and Flagship Pioneering.

Transaction Overview

Company Name
Acceleron Pharma
Announced On
10/30/2007
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Series C
Investors

Bessemer Venture Partners (Lead Investor) (Christopher Gabrielli)

Advanced Technology Ventures (Jean George)

Flagship Pioneering (Ed Kania)

MPM Capital

OrbiMed (Carl Gordon)

Polaris Partners (Terry McGuire)

QVT Fund

Sutter Hill Ventures

Venrock (Tony Evnin)

Proceeds Purpose
Acceleron plans to use the proceeds from this financing to advance its clinical and preclinical pipeline and further develop its product platform. In the first quarter of 2008, Acceleron expects to advance its ACE-011 program for bone growth into phase 2 clinical trials and to initiate a phase 1 study of its ACE-031 program for increasing muscle mass and strength. The company expects to bring its third drug candidate, ACE-041, into clinical trials in the second half of 2008.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
128 Sidney St.
Cambridge, MA 02139
USA
Phone
(617) 649-9200
Website
www.acceleronpharma.com
Email Address
[email protected]
Overview
Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body's remarkable capacity for cellular growth and repair.
Profile
Acceleron Pharma LinkedIn Company Profile
Social Media
Acceleron Pharma Company Twitter Account
Company News
Acceleron Pharma News
Facebook
Acceleron Pharma on Facebook
YouTube
Acceleron Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Habib Dable
  Habib Dable LinkedIn Profile  Habib Dable Twitter Account  Habib Dable News  Habib Dable on Facebook
Chief Financial Officer
Kevin McLaughlin
  Kevin McLaughlin LinkedIn Profile  Kevin McLaughlin Twitter Account  Kevin McLaughlin News  Kevin McLaughlin on Facebook
Chief Scientific Officer
Ravi Kumar
  Ravi Kumar LinkedIn Profile  Ravi Kumar Twitter Account  Ravi Kumar News  Ravi Kumar on Facebook
Vice President
Todd James
  Todd James LinkedIn Profile  Todd James Twitter Account  Todd James News  Todd James on Facebook
VP - Bus. Development
Sujay Kango
  Sujay Kango LinkedIn Profile  Sujay Kango Twitter Account  Sujay Kango News  Sujay Kango on Facebook
VP - Bus. Development
John Quisel
  John Quisel LinkedIn Profile  John Quisel Twitter Account  John Quisel News  John Quisel on Facebook
VP - Bus. Development
Tracey Sacco
  Tracey Sacco LinkedIn Profile  Tracey Sacco Twitter Account  Tracey Sacco News  Tracey Sacco on Facebook
VP - General Counsel
Adam Veness
  Adam Veness LinkedIn Profile  Adam Veness Twitter Account  Adam Veness News  Adam Veness on Facebook
VP - Human Resources
Kevin McManus
  Kevin McManus LinkedIn Profile  Kevin McManus Twitter Account  Kevin McManus News  Kevin McManus on Facebook
VP - Regulatory Affairs
James Desiderio
  James Desiderio LinkedIn Profile  James Desiderio Twitter Account  James Desiderio News  James Desiderio on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/30/2007: Dataupia venture capital transaction
Next: 10/30/2007: ImageTree venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.